United States (USA) Vaccines Market Overview, 2028

United States (USA) Vaccines Market Overview, 2028

Vaccines have had a profound impact on public health in the United States. The introduction of vaccines has led to the eradication or near-elimination of diseases like smallpox, polio, and measles. The U.S. has one of the most comprehensive immunisation schedules in the world, recommending vaccines for children, adolescents, and adults. The schedule is regularly updated to reflect the latest scientific evidence and vaccine advancements. The United States is a major hub for vaccine research and development. It is home to numerous pharmaceutical companies, research institutions, and academic centres dedicated to vaccine innovation. The U.S. has robust vaccine safety monitoring systems, including the Vaccine Adverse Event Reporting System (VAERS) and the Vaccine Safety Datalink (VSD). These systems continually monitor vaccine safety. Vaccination is not just for children in the U.S. Adults are encouraged to receive vaccines for diseases like influenza, shingles, pneumococcal disease, and COVID-19, highlighting the importance of lifelong immunization. While vaccination is encouraged, some U.S. states have laws allowing for exemptions based on religious or philosophical beliefs. These laws have sparked debates about vaccine mandates and exemptions. The U.S. government, healthcare organisations, and advocacy groups run public awareness campaigns to educate the public about the importance of vaccination and dispel vaccine myths. Despite high vaccination coverage for many diseases, the U.S. has faced challenges with vaccine hesitancy and pockets of under vaccinated populations, leading to outbreaks of vaccine-preventable diseases in some communities.

According to the research report ""United States of America Vaccines Market Overview, 2028,"" published by Bonafide Research, the United States of America Vaccines Market was valued at more than USD 22 Billion in 2022. The U.S. government, through agencies like the Centres for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), plays a crucial role in supporting vaccination efforts. They provide recommendations, regulate vaccine approvals, and oversee immunisation programs. The USA has a comprehensive immunisation schedule that recommends a wide range of vaccines for different age groups. This schedule helps ensure that individuals receive the necessary vaccinations at the right time. The USA is a global leader in vaccine research and development. It is home to numerous pharmaceutical companies, research institutions, and academic centres that contribute to vaccine innovation and advancement. Health insurance coverage, including public programmes like Medicaid and private insurance plans, often includes coverage for vaccines. This makes vaccines accessible and affordable for many individuals. The USA actively participates in global health initiatives and contributes to international efforts to combat vaccine-preventable diseases. This includes support for vaccination programmes in low- and middle-income countries. Public health campaigns and educational efforts play a crucial role in promoting vaccination. These initiatives inform the public about the importance of vaccines, address concerns, and encourage adherence to recommended immunisation schedules. The vaccination schedule for new-borns in the USA is recommended by the Centres for Disease Control and Prevention (CDC) and the American Academy of Paediatrics (AAP). This schedule provides guidance on when and which vaccines should be administered. The first vaccine a new-born typically receives is the hepatitis B vaccine. It is administered shortly after birth, often within the first 24 hours. This vaccine helps protect against hepatitis B, a viral infection that can lead to liver disease.

Based on the technology includes, they include conjugated vaccines, inactivated and subunit vaccines, live-attenuated vaccines, recombinant vaccines, and toxoid vaccines. In the USA, conjugate vaccines are more commonly used in the market; they are leading the market with the highest market share. Conjugate vaccines have demonstrated exceptional effectiveness against bacterial diseases caused by encapsulated bacteria. These vaccines can prevent serious and potentially life-threatening infections, particularly in infants and young children. Many conjugate vaccines are specifically designed for paediatric use. They are administered to infants and young children as part of routine immunisation schedules. Diseases targeted by these vaccines, such as Haemophilus influenza type b (Hib) and Streptococcus pneumonias, are more common and severe in this age group. Achieving high vaccination coverage with conjugate vaccines contributes to herd immunity, reducing the overall transmission of targeted bacteria within communities. This helps protect vulnerable populations, including those who cannot receive vaccines due to medical conditions. The U.S. has well-established government-led immunisation programmes, such as the Vaccines for Children (VFC) programme, which provides vaccines to eligible children for free or at a reduced cost. Conjugate vaccines are integral to these programmes, ensuring widespread access.

In terms of the end user segment, which includes adults and paediatrics, in the USA, paediatrics has the highest market share, and the United States places a strong emphasis on childhood immunisation as a fundamental component of public health. Vaccinating children at a young age helps establish immunity to a range of serious and potentially life-threatening diseases. Many vaccine-preventable diseases, such as measles, mumps, rubella, pertussis, and Haemophilus influenzae type B (Hib), can cause severe complications in infants and young children. Vaccination provides critical protection during this vulnerable period. Many states in the USA have immunisation requirements for school entry. This means that children need to be up-to-date on their vaccinations before starting school, reinforcing the importance of paediatric immunization. Parents are typically highly motivated to ensure the health and well-being of their children. This includes adhering to recommended vaccination schedules and seeking out necessary immunisations for their infants and young children. Vaccinating children not only protects them in the short term but also lays the foundation for a lifetime of good health. Many childhood vaccines provide long-lasting immunity, reducing the risk of serious diseases in adulthood.

According to the report, the distribution channel is segmented on the basis of hospital pharmacy, retail pharmacy, institutional sales, and others. In the USA market, hospital pharmacy is the leading market. Hospitals are integral components of the healthcare infrastructure in the USA. They have the facilities, equipment, and trained healthcare personnel required for proper vaccine storage, handling, and administration. Hospitals are trusted healthcare institutions. Patients often feel more confident in the safety and efficacy of vaccines when they receive them in a hospital setting, which can positively influence vaccine acceptance. Some U.S. government programmes collaborate with hospitals to distribute vaccines as part of national immunisation efforts. Hospitals receive government support and incentives to participate in these programs. Furthermore, there are many hospitals and pharmacies that provide the vaccines in the USA, including the Mayo Clinic, Cleveland Clinic, Walgreens, and many more. According to the report types are segmented into the Multivalent vaccines and Monovalent vaccines among them in the USA the Multivalent vaccines is leading market, Combination vaccines reduce the number of injections a person needs to receive to be protected against multiple diseases. This is particularly beneficial for infants and children who may require numerous vaccinations in their early years. Combining vaccines can result in cost savings for healthcare systems and providers by reducing the need for multiple office visits and separate vaccine purchases. Multivalent vaccines are often used in public health programs to increase vaccination coverage rates, especially in populations with limited access to healthcare services.

Based on the route of administration are segmented into the Intramuscular and Subcutaneous, Administration, Oral Administration and Others. In Country the Oral Administration is growing market, Oral vaccines are typically administered as liquids or tablets, making them easier to administer than injections. This can reduce the need for trained healthcare personnel and eliminate the risk of needlestick injuries. Many people, especially children and those with needle phobias, prefer oral vaccines over injections. This can lead to higher vaccination rates and better overall public health outcomes. In terms of the Disease types includes the Rotavirus, Pneumococcal diseases, Cancer, Influenza, Diphtheria, Pertussis, and Tetanus, Human Papilloma Virus (HPV), Hepatitis, Shingles, Meningococcal diseases, Varicella, Mumps and Others. In USA the Human Papilloma Virus will grow with the highest rate of cagr rate, public health campaigns and educational initiatives aimed at increasing awareness about the risks of HPV infection and its link to cervical and other cancers have led to increased demand for HPV vaccination. The Advisory Committee on Immunization Practices (ACIP), a division of the Centers for Disease Control and Prevention (CDC), recommended routine HPV vaccination for both males and females at a young age. This recommendation increased the uptake of the HPV vaccine. The HPV vaccine was initially approved for the prevention of cervical cancer, but its indications were expanded to include protection against other HPV-related cancers, such as anal, penile, and oropharyngeal cancers. This expansion broadened the market for HPV vaccines.

Recent products launch:
• In 2023, two respiratory syncytial virus (RSV) vaccines were launched in the USA, Beyfortus (Sanofi) and Arexvy (GSK). RSV is a common virus that can cause serious respiratory illness in infants and young children.
• In 2023, the FDA approved updated mRNA COVID-19 vaccines from Pfizer-BioNTech and Moderna. These vaccines are designed to be more effective against the currently circulating Omicron variant.
• In 2021, the FDA approved the world's first malaria vaccine, Mosquirix (GlaxoSmithKline). Mosquirix is a four-dose vaccine that is recommended for children in malaria-endemic countries.
• In 2020, the FDA approved the first Zika vaccine, VLA1553 (Takeda). VLA1553 is an investigational vaccine that is still in clinical trials. It is not yet commercially available.

Considered in this report:
• Geography: United States of America
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• United States of America Vaccines market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Technology
• Conjugate vaccines
• Inactivated & Subunit vaccines
• Live Attenuated vaccines
• Recombinant vaccines
• Toxoid vaccines
• Viral vector vaccines
• Others

By End-User Type
• Paediatrics
• Adults

By Route of Administration
• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

By Disease
• Rotavirus
• Pneumococcal diseases
• Cancer
• Influenza
• Diphtheria, Pertussis, and Tetanus (DTP)
• Human Papilloma Virus (HPV)
• Hepatitis
• Shingles
• Meningococcal diseases
• Varicella (Chicken Pox)
• Mumps
• Others

By Type
• Multivalent vaccines
• Monovalent vaccines

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Drone industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.